Visual Abstract

Background: Risk factors of mortality in chronic hemodialysis patients have not yet been sufficiently evaluated. In particular, chronological transits and interactions of the impact of risk factors have rarely been described. Methods: This study is a post hoc analysis of the participants in the Olme-sartan Clinical Trial in Okinawan Patients under OKIDS (OCTOPUS) study conducted between June 2006 and June 2011. We additionally followed up on the prognosis of the participants until July 31, 2018. Standardized univariable and multivariable Cox regression analyses were used to evaluate the influences of the participants’ baseline characteristics on all-cause mortality. We also evaluated chronological changes in the impacts of risk factors, interactions among predictors, and the influence of missing values using sensitivity analyses. Results: Of the 469 original trial participants, 461 participants were evaluated. The median time of follow-up was 10.2 years. A total of 211 (45.8%) participants were deceased. The leading causes of death were infection (n = 72, 34.1%) and cardiovascular disease (n = 66, 31.3%). Univariate and multivariate Cox regression analyses revealed that the impact of diabetes mellitus, history of coronary intervention, and hypoalbuminemia were significant risk factors for mortality during the whole follow-up period. During the early follow-up period (≤3 years), standardized univariate Cox regression analyses revealed that history of amputation (hazard ratio [HR] = 4.61, p < 0.001), lower dry weight, higher cardiothoracic ratio, and lower potassium levels were statistically significant risks. In those who survived for longer than 3 years, a history of stroke (HR = 1.73, p = 0.006), higher systolic blood pressure, lower serum sodium levels, and higher levels of hemoglobin, and serum phosphate were significant risks. We also observed a stable interaction between the impacts of serum phosphate and albumin on all-cause mortality. Conclusion: In chronic hemodialysis patients, targets to improve the short-term prognosis and long-term prognosis are not equivalent. Hyperphosphatemia was a significant risk factor for the all-cause mortality among patients with normal serum albumin levels but not among patients with compromised albumin levels.

1.
Saran
R
,
Robinson
B
,
Abbott
KC
,
Agodoa
LY
,
Albertus
P
,
Ayanian
J
, et al.
US renal data system 2016 annual data report: epidemiology of kidney disease in the United States
.
Am J Kidney Dis
.
2017
;
69
(
3 Suppl 1
):
A7
8
. .
2.
Yaseen
M
,
Hassan
W
,
Awad
R
,
Ashqar
B
,
Neyra
J
,
Heister
T
, et al.
Impact of recent clinical trials on nephrology practice: are we in a stagnant era?
Kidney Dis
.
2019
;
5
(
2
):
69
80
. .
3.
Chatzimanouil
MKT
,
Wilkens
L
,
Anders
HJ
.
Quantity and reporting quality of kidney research
.
J Am Soc Nephrol
.
2019
;
30
(
1
):
13
22
. .
4.
Ajiro
J
,
Alchi
B
,
Narita
I
,
Omori
K
,
Kondo
D
,
Sakatsume
M
, et al.
Mortality predictors after 10 years of dialysis: a prospective study of Japanese hemodialysis patients
.
Clin J Am Soc Nephrol
.
2007
;
2
(
4
):
653
60
. .
5.
Haapio
M
,
Helve
J
,
Grönhagen-Riska
C
,
Finne
P
.
One- and 2-year mortality prediction for patients starting chronic dialysis
.
Kidney Int Rep
.
2017
;
2
(
6
):
1176
85
. .
6.
Forzley
B
,
Er
L
,
Chiu
HHL
,
Djurdjev
O
,
Martinusen
D
,
Carson
RC
, et al.
External validation and clinical utility of a prediction model for 6-month mortality in patients undergoing hemodialysis for end-stage kidney disease
.
Palliat Med
.
2018
;
32
(
2
):
395
403
. .
7.
Iseki
K
,
Tokuyama
K
,
Shiohira
Y
,
Higa
A
,
Hirano
H
,
Toma
S
, et al.
Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods
.
Clin Exp Nephrol
.
2009
;
13
(
2
):
145
51
. .
8.
Iseki
K
,
Arima
H
,
Kohagura
K
,
Komiya
I
,
Ueda
S
,
Tokuyama
K
, et al.
Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial
.
Nephrol Dial Transplant
.
2013
;
28
(
6
):
1579
89
. .
9.
Hirakata
H
,
Nitta
K
,
Tomo
M
,
Akiba
T
,
Ikari
Y
,
Iseki
K
, et al.
Clinical guidelines for the evaluation and the treatment of cardiovascular complications in hemodialysis patients
.
J Jpn Soc Dial Ther
.
2011
;
44
(
5
):
337
425
.
10.
Barthel
FM
,
Royston
P
.
Graphical representation of interactions
.
Stata J
.
2006
;
6
(
3
):
348
63
. .
11.
Iseki
K
,
Nakai
S
,
Shinzato
T
,
Morita
O
,
Shinoda
T
,
Kikuchi
K
, et al.
Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan
.
Ther Apher Dial
.
2007
;
11
(
3
):
183
8
. .
12.
Nakao
K
,
Makino
H
,
Morita
S
,
Takahashi
Y
,
Akizawa
T
,
Saito
A
, et al.
Beta-blocker prescription and outcomes in hemodialysis patients from the Japan dialysis outcomes and practice patterns study
.
Nephron Clin Pract
.
2009
;
113
(
3
):
c132
9
. .
13.
Frankenfield
DL
,
Weinhandl
ED
,
Powers
CA
,
Howell
BL
,
Herzog
CA
,
St Peter
WL
.
Utilization and costs of cardiovascular disease medications in dialysis patients in medicare part D
.
Am J Kidney Dis
.
2012
;
59
(
5
):
670
81
. .
14.
Terada
T
,
Forhan
M
,
Norris
CM
,
Qiu
W
,
Padwal
R
,
Sharma
AM
, et al.
Differences in short- and long-term mortality associated with BMI following coronary revascularization
.
J Am Heart Assoc
.
2017
;
6
(
4
):
e005335
. .
15.
Qureshi
AR
,
Alvestrand
A
,
Divino-Filho
JC
,
Gutierrez
A
,
Heimbürger
O
,
Lindholm
B
, et al.
Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients
.
J Am Soc Nephrol
.
2002
;
13
(
Suppl 1
):
S28
36
.
16.
Cooper
BA
,
Penne
EL
,
Bartlett
LH
,
Pollock
CA
.
Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD
.
Am J Kidney Dis
.
2004
;
43
(
1
):
61
6
. .
17.
Genovesi
S
,
Porcu
L
,
Luise
MC
,
Riva
H
,
Nava
E
,
Contaldo
G
, et al.
Sudden death in end stage renal disease: comparing hemodialysis versus peritoneal dialysis
.
Blood Purif
.
2017
;
44
(
1
):
77
88
. .
18.
Msaad
R
,
Essadik
R
,
Mohtadi
K
,
Meftah
H
,
Lebrazi
H
,
Taki
H
, et al.
Predictors of mortality in hemodialysis patients
.
Pan Afr Med J
.
2019
;
33
:
61
. .
19.
Shi
C
,
Liu
S
,
Yu
HF
,
Han
B
.
Glycemic variability and all-cause mortality in patients with diabetes receiving hemodialysis: a prospective cohort study
.
J Diabetes Complications
.
2020
;
34
(
4
):
107549
. .
20.
Arhuidese
I
,
Nejim
B
,
Aji
EA
,
Canner
J
,
Malas
MB
.
Survival after major lower extremity amputation in patients with end-stage renal disease
.
J Vasc Surg
.
2019
;
70
(
4
):
1291
8
. .
21.
Endo
M
,
Nakamura
Y
,
Murakami
T
,
Tsukahara
H
,
Watanabe
Y
,
Matsuoka
Y
, et al.
Rehabilitation improves prognosis and activities of daily living in hemodialysis patients with low activities of daily living
.
Phys Ther Res
.
2017
;
20
(
1
):
9
15
. .
22.
Post
A
,
Tsikas
D
,
Bakker
SJL
.
Creatine is a conditionally essential nutrient in chronic kidney disease: a hypothesis and narrative literature review
.
Nutrients
.
2019
;
11
(
5
):
1044
. .
23.
Tufan
F
,
Yıldız
A
,
Dogan
I
,
Yıldız
D
,
Sevinir
Ş
.
Urea to creatinine ratio: a forgotten marker of poor nutritional state in patients undergoing hemodialysis treatment
.
Aging Male
.
2015
;
18
(
1
):
49
53
. .
24.
Lee
S
,
Kang
E
,
Yoo
KD
,
Choi
Y
,
Kim
DK
,
Joo
KW
, et al.
Lower serum potassium associated with increased mortality in dialysis patients: a nationwide prospective observational cohort study in Korea
.
PLoS One
.
2017
;
12
(
3
):
e0171842
. .
25.
Ito
K
,
Ookawara
S
,
Ueda
Y
,
Miyazawa
H
,
Yamada
H
,
Goto
S
, et al.
A higher cardiothoracic ratio is associated with 2-year mortality after hemodialysis initiation
.
Nephron Extra
.
2015
;
5
(
3
):
100
10
. .
26.
Iseki
K
,
Fukiyama
K
;
Okawa Dialysis Study G
.
Clinical demographics and long-term prognosis after stroke in patients on chronic haemodialysis. The Okinawa Dialysis Study (OKIDS) group
.
Nephrol Dial Transplant
.
2000
;
15
(
11
):
1808
13
. .
27.
Robinson
BM
,
Tong
L
,
Zhang
J
,
Wolfe
RA
,
Goodkin
DA
,
Greenwood
RN
, et al.
Blood pressure levels and mortality risk among hemodialysis patients in the dialysis outcomes and practice patterns study
.
Kidney Int
.
2012
;
82
(
5
):
570
80
. .
28.
Bansal
N
,
McCulloch
CE
,
Rahman
M
,
Kusek
JW
,
Anderson
AH
,
Xie
D
, et al.
Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study
.
Hypertension
.
2015
;
65
(
1
):
93
100
. .
29.
Sars
B
,
van der Sande
FM
,
Kooman
JP
.
Intradialytic hypotension: mechanisms and outcome
.
Blood Purif
.
2020
;
49
(
1–2
):
158
67
. .
30.
Sun
L
,
Hou
Y
,
Xiao
Q
,
Du
Y
.
Association of serum sodium and risk of all-cause mortality in patients with chronic kidney disease: a meta-analysis and sysematic review
.
Sci Rep
.
2017
;
7
(
1
):
15949
. .
31.
Rhee
CM
,
Ayus
JC
,
Kalantar-Zadeh
K
.
Hyponatremia in the dialysis population
.
Kidney Int Rep
.
2019
;
4
(
6
):
769
80
. .
32.
Kido
R
,
Akizawa
T
,
Fukuhara
S
.
Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS)
.
BMJ Open
.
2019
;
9
(
9
):
e031476
. .
33.
Harford
AM
,
Zager
PG
.
Mortality risk in dialysis patients with naturally higher hemoglobins
.
J Am Soc Nephrol
.
2011
;
22
(
2
):
205
6
. .
34.
Block
GA
,
Hulbert-Shearon
TE
,
Levin
NW
,
Port
FK
.
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study
.
Am J Kidney Dis
.
1998
;
31
(
4
):
607
17
. .
35.
Lee
JE
,
Lim
JH
,
Jang
HM
,
Kim
YS
,
Kang
SW
,
Yang
CW
, et al.
Low serum phosphate as an independent predictor of increased infection-related mortality in dialysis patients: a prospective multicenter cohort study
.
PLoS One
.
2017
;
12
(
10
):
e0185853
. .
36.
Ye
X
,
Kooman
JP
,
van der Sande
FM
,
Raimann
JG
,
Usvyat
LA
,
Wang
Y
, et al.
Relationship between serum phosphate levels and survival in chronic hemodialysis patients: interactions with age, malnutrition and inflammation
.
Clin Kidney J
.
2021
;
14
;
348
57
. .
37.
Zitt
E
,
Lamina
C
,
Sturm
G
,
Knoll
F
,
Lins
F
,
Freistätter
O
, et al.
Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients
.
Clin J Am Soc Nephrol
.
2011
;
6
(
11
):
2650
6
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.